Roche Holding AG banner

Roche Holding AG
SIX:ROG

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
SIX:ROG
Watchlist
Price: 324.9 CHF 4.13% Market Closed
Market Cap: CHf262.9B

P/B

7.7
Current
5%
More Expensive
vs 3-y average of 7.3

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
7.7
=
Market Cap
CHf279.8B
/
Total Equity
CHf33.8B

Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.

P/B
7.7
=
Market Cap
CHf279.8B
/
Total Equity
CHf33.8B

Valuation Scenarios

Roche Holding AG is trading above its 3-year average

If P/B returns to its 3-Year Average (7.3), the stock would be worth CHf310.9 (4% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-68%
Maximum Upside
No Upside Scenarios
Average Downside
23%
Scenario P/B Value Implied Price Upside/Downside
Current Multiple 7.7 CHf324.9
0%
3-Year Average 7.3 CHf310.9
-4%
5-Year Average 7.5 CHf319.28
-2%
Industry Average 6.2 CHf264.64
-19%
Country Average 2.5 CHf105.06
-68%

Forward P/B
Today’s price vs future total equity

Not enough data available to calculate forward P/B

Peer Comparison

All Multiples
P/B
P/E
All Countries
Close

Market Distribution

Higher than 85% of companies in Switzerland
Percentile
85th
Based on 1 079 companies
85th percentile
7.7
Low
0 — 1.4
Typical Range
1.4 — 4.5
High
4.5 —
Distribution Statistics
Switzerland
Min 0
30th Percentile 1.4
Median 2.5
70th Percentile 4.5
Max 69.1

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

ROG Intrinsic Value
416.39 CHF
Undervaluation 22%
Intrinsic Value
Price CHf324.9
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett